BB305 Lentiviral Vector

· Genetix Biotherapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BB305 Lentiviral Vector, covering 2024-12-10 to 2024-12-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease [Phase 3]